The Leadership Core provides the overall context for the translational activities of the SPORE and builds on established interdisciplinary collaborations. Dr. Porter and Dr. Cheever, Co-PIs of the SPORE, will co-direct the Core and lead an Executive Committee (EC), composed of all Project and Core leaders and breast cancer patient advocates, primarily responsible for overall planning and evaluation. The EC will be advised on scientific direction, planning and evaluation of the translational progress of SPORE projects and activities by both an External Advisory Board (EAB), which includes three national SPORE leaders, and an Internal Advisory Board (lAB), which include two SPORE leaders. To maintain a high degree of translational research focus to all SPORE activities, the EC will meet and interact regularly with the SPORE Career Development Program (CDP) and Developmental Research Program (DRP) committees, and the SPORE Statistical Working Group (SWG).
The aims of the Administrative Core are to: 1. Provide oversight of all SPORE activities to meet the scientific and administrative needs of the individual research projects and cores 2. In consultation with EAB members, integrate new projects into the SPORE 3. Provide an organizational structure within the FHCRC/UW Cancer Consortium (Consortium), which a. promotes interaction between interdisciplinary investigators, in and outside of the SPORE b. evaluates progress towards translational goals c. encourages, selects and guides new research and developmental projects d. provides career mentorshlp and entry of women and minorities into the field of breast cancer research 4. Promote SPORE-SPORE interactions, within and outside the Consortium 5. Provide fiscal management of grant funds and records in compliance with all regulations and requirements, including Radiation Safety, Animal Care, and Protection of Human Subjects 6. Communicate and consult with NCI project officers and staff in preparation of required progress reports, publications and regulatory documents

Public Health Relevance

The structure and make up of the Leadership Core brings diverse groups together for planning, development of new projects, career development and support and offers a plan for evaluation of the success in building a truly translational breast cancer research program within the SPORE mechanism.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA138293-05
Application #
8728125
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
5
Fiscal Year
2014
Total Cost
$132,852
Indirect Cost
$55,201
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Berger, Carolina; Sommermeyer, Daniel; Hudecek, Michael et al. (2015) Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells. Cancer Immunol Res 3:206-16
Stephan, Sirkka B; Taber, Alexandria M; Jileaeva, Ilona et al. (2015) Biopolymer implants enhance the efficacy of adoptive T-cell therapy. Nat Biotechnol 33:97-101
Jensen, Michael C; Riddell, Stanley R (2014) Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells. Immunol Rev 257:127-44
Marcondes, A Mario; Karoopongse, Ekapun; Lesnikova, Marina et al. (2014) ?-1-Antitrypsin (AAT)-modified donor cells suppress GVHD but enhance the GVL effect: a role for mitochondrial bioenergetics. Blood 124:2881-91
Partridge, Savannah C; Stone, Karen M; Strigel, Roberta M et al. (2014) Breast DCE-MRI: influence of postcontrast timing on automated lesion kinetics assessments and discrimination of benign and malignant lesions. Acad Radiol 21:1195-203
Riddell, Stanley R; Sommermeyer, Daniel; Berger, Carolina et al. (2014) Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition. Cancer J 20:141-4
Kennedy, Jacob J; Abbatiello, Susan E; Kim, Kyunggon et al. (2014) Demonstrating the feasibility of large-scale development of standardized assays to quantify human proteins. Nat Methods 11:149-55
Hudecek, Michael; Lupo-Stanghellini, Maria-Teresa; Kosasih, Paula L et al. (2013) Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin Cancer Res 19:3153-64
Sun, Jianping; Zheng, Yingye; Hsu, Li (2013) A unified mixed-effects model for rare-variant association in sequencing studies. Genet Epidemiol 37:334-44
Qu, Xiaoyu; Randhawa, Grace; Friedman, Cynthia et al. (2013) A three-marker FISH panel detects more genetic aberrations of AR, PTEN and TMPRSS2/ERG in castration-resistant or metastatic prostate cancers than in primary prostate tumors. PLoS One 8:e74671

Showing the most recent 10 out of 14 publications